The new product of NPO Microgen, a subsidiary of Nacimbio pharmaceutical holding company (a part of Rostec Corporation), is the first Russian live influenza vaccine in liquid form that does not require intramuscular injections.
The drug has passed the first phase of clinical trials, which confirmed its safety. New product is part of the holding company’s strategy to modernize and expand the product portfolios of its enterprises with the drugs that reduce the injection load on patients and, first of all, children.
“One of the key challenges currently being addressed by the world pharmaceutical community is how to discover and create new forms of drugs that would reduce the traumatic nature of therapy. Our new influenza vaccine in the form of spray administered into the nicrmmiose of patient will significantly simplify immunization by making the process faster, more comfortable, and safe,” said Kirill Gaidash, General Director of NPO Microgen.
New vaccine is based on Ultravac, a live influenza vaccine that was successfully used in fighting the influenza pandemic and is produced by NPO Microgen in the form of dry substance for solution.
The drug was extensively used in clinical practice, with more than 100 million vaccinated people in Russia. Unlike Ultravac, the new product does not require to mix active substance with the solvent, as it will be produced in finished liquid dosage form.